CD8A and influenza: Nevertheless, safe adjuvants that promote the response of CD8+ T cells might find application in universal influenza vaccines, during pandemics (where fast cross-protective responses and antigen dose sparing are required) and to improve protection of high-risk groups that respond poorly to the licensed influenza vaccines (e.g., elderly)7,59.